August 6, 2026, Suzhou, China – Porton Advanced, a leading cell and gene therapy CDMO in China, today announced a strategic partnership with Yeasen, a leading biotechnology company specializing in protein engineering and directed evolution technology.The collaboration will focus on custom transfection reagent development, joint quality control product validation, and market synergies to bridge upstream critical raw materials with CDMO services, delivering more efficient and cost-competitive one-stop cell and gene therapy solutions to global clients.
As the CGT industry enters a critical phase of commercialization, supply chain security for core raw materials has become a strategic industry priority. As a leading CGT CDMO player, Porton Advanced offers an end-to-end platform covering plasmids, viral vectors, cell therapy, gene therapy, nucleic acid therapeutics, and exosomes, supporting clients across the full product lifecycle from IND filing and clinical research through to commercial manufacturing. Yeasen, with its deep expertise in molecular enzymes and quality control reagents, develops and scales its own core raw material products，including transfection reagents and detection kits，which are widely used in life science research and biopharmaceutical applications.
This partnership will create a seamless integration from upstream core raw materials to downstream CMC development and manufacturing, building a more robust value chain for the industry.
Porton Advanced is committed to building a resilient and diversified global supply chain. By deepening strategic collaborations with key raw material suppliers, the company continues to enhance industrial chain resilience, mitigate the commercial risks associated with single-source dependency or high production costs, and accelerate patient access to advanced therapies. To date, the company has established a multi-source supply network for critical materials, significantly enhanced supply chain flexibility and resilience.
Andrew Chen, CEO of Porton Advanced, stated, “Yeasen brings an advanced technology platform and high-quality products that are highly complementary to our CDMO platform, particularly in transfection and quality control reagents. This strategic partnership not only strengthens the stability and competitiveness of our supply chain but also represents a significant step forward in our efforts to optimize the CGT industry ecosystem. We look forward to working with Yeasen to provide our clients with one-stop services from raw materials to commercial manufacturing, fulfilling our mission of making good medicines available to patients sooner.”
Weihua Huang, Founder and Chairman of Yeasen, commented,“Porton Advance is a recognized leader in China’s CGT CDMO sector, with outstanding platform capabilities and a strong track record of project delivery. We are delighted to enter into this strategic partnership. Yeasen has always been committed to delivering high-quality enabling products, and this collaboration will embed us more deeply into the CGT drug development value chain, accelerating the validation and adoption of core raw materials in real-world manufacturing settings. By harnessing our raw material and technology strengths, we look forward to helping Porton BioPorton Advanced and our shared customers reduce costs, improve efficiency, and create greater value together.”
This strategic partnership marks a new beginning for mutual growth and shared success. Moving forward, Porton Advanced and Yeasen will work together, leveraging their enhanced integrated capabilities to empower global biopharmaceutical innovators and drive the robust development of the CGT industry.
Yeasen Biotechnology is a leading biotechnology company specializing in protein engineering and directed evolution technology. Since its establishment in 2014, Yeasen has been dedicated to the advancement of molecular enzymes and proteins within the life science sector. Leveraging our proprietary materials, we have undertaken the development of enzyme and reagents across three key categories: molecules, proteins, and cellular biology. These products cater to the demands of the life science research, molecular diagnostics, and biopharmaceutical industries. Over more than 10 years, Yeasen has evolved into a distinguished international high-tech enterprise, boasting self-reliant research and development as well as manufacturing capabilities.
Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, Investigator-initiated Clinical Trial Services (IITs), and Investigational New Drug (IND) applications to clinical trials, New Drug Applications (NDA), and commercialization.
Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV, etc.), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc., bacterial vector and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector GMP-compliant production lines, 12 cell therapy GMP-compliant production suites (2 for commercial products). As of now, we have successfully supported our clients to secure 26 global IND approvals from NMPA, FDA, and Medsafe, with 12 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.
Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling earlier access to good medicines.
August 6, 2026, Suzhou, China –Porton Advanced Solutions Ltd. ("Porton Advanced") and Yeasen Biotechnology Co., Ltd. ("Yeasen") today announced a strategic partnership. The collaboration will focus on custom transfection reagent development, joint quality control product validation, and market synergies to bridge upstream critical raw materials with CDMO services, delivering more efficient and cost-competitive one-stop cell and gene therapy (CGT) solutions to global clients.
As the CGT industry enters a critical phase of commercialization, supply chain security for core raw materials has become a strategic industry priority. As a leading CGT CDMO player, Porton Advanced offers an end-to-end platform covering plasmids, viral vectors, cell therapy, gene therapy, nucleic acid therapeutics, and exosomes, supporting clients across the full product lifecycle from IND filing and clinical research through to commercial manufacturing. Yeasen, with its deep expertise in molecular enzymes and quality control reagents, develops and scales its own core raw material products—including transfection reagents and detection kits—which are widely used in life science research and biopharmaceutical applications.
This partnership will create a seamless integration from upstream core raw materials to downstream CMC development and manufacturing, building a more robust value chain for the industry.
Porton Advanced is committed to building a resilient and diversified global supply chain. By deepening strategic collaborations with key raw material suppliers, the company continues to enhance industrial chain resilience, mitigate the commercial risks associated with single-source dependency or high production costs, and accelerate patient access to advanced therapies. To date, the company has established a multi-source supply network for critical materials, significantly enhanced supply chain flexibility and resilience.
Andrew Chen, CEO of Porton Advanced, commented, "Yeasen possesses advanced technological platforms and high-quality products, which are highly complementary to our CDMO platform, particularly in the areas of transfection and quality control reagents. This strategic partnership not only strengthens the stability and competitiveness of our supply chain but also represents a significant step forward in our efforts to drive localization and optimize the CGT industry ecosystem. We look forward to working with Yeasen to provide our clients with one-stop services from raw materials to commercial manufacturing, fulfilling our mission of making good medicines available to patients sooner."
Weihua Huang, Founder and Chairman of Yeasen, commented,“Porton Advance is a recognized leader in China’s CGT CDMO sector, with outstanding platform capabilities and a strong track record of project delivery. We are delighted to enter into this strategic partnership. Yeasen has always been committed to delivering high-quality enabling products, and this collaboration will embed us more deeply into the CGT drug development value chain, accelerating the validation and adoption of core raw materials in real-world manufacturing settings. By harnessing our raw material and technology strengths, we look forward to helping Porton BioPorton Advanced and our shared customers reduce costs, improve efficiency, and create greater value together.”
This strategic partnership marks a new beginning for mutual growth and shared success. Moving forward, Porton Advanced and Yeasen will work together, leveraging their enhanced integrated capabilities to empower global biopharmaceutical innovators and drive the robust development of the CGT industry.
Yeasen Biotechnology is a leading biotechnology company specializing in protein engineering and directed evolution technology. Since its establishment in 2014, Yeasen has been dedicated to the advancement of molecular enzymes and proteins within the life science sector. Leveraging our proprietary materials, we have undertaken the development of enzyme and reagents across three key categories: molecules, proteins, and cellular biology. These products cater to the demands of the life science research, molecular diagnostics, and biopharmaceutical industries. Over more than 10 years, Yeasen has evolved into a distinguished international high-tech enterprise, boasting self-reliant research and development as well as manufacturing capabilities.
Porton Advanced Solutions is a subsidiary of the leading CDMO, Porton Pharma Solutions. Porton Advanced has headquarters in Cranbury, New Jersey, and two GMP sites in Suzhou, China, providing end-to-end CDMO solutions for ATMPs. We offer services from cell banking, process, and analytical method development, cGMP production to fill & finish, covering different stages of drug development from early research, Investigator-initiated Clinical Trial Services (IITs), and Investigational New Drug (IND) applications to clinical trials, New Drug Applications (NDA), and commercialization.
Porton Advanced has developed specialized CRO and CDMO platforms focusing on plasmids, viral vectors (lentiviral vector, adenoviral vector, AAV, etc.), cell therapy CMC services including CAR-T, TCR-T, CAR-NK, HSC, exosome, etc., bacterial vector and nucleic acid therapies. Our state-of-the-art, GMP-compliant facilities span an impressive 215,000 sq ft, equipped with 10 viral vector GMP-compliant production lines, 12 cell therapy GMP-compliant production suites (2 for commercial products). As of now, we have successfully supported our clients to secure 26 global IND approvals from NMPA, FDA, and Medsafe, with 12 ongoing Phase I/II ATMP projects. Additionally, Porton Advanced has supported the successful transition of several overseas clinical-stage pipelines into China.
Porton Advanced is committed to a customer-centric approach, offering excellent global, end-to-end CDMO services to our clients, enabling earlier access to good medicines.
Porton Advanced Secures Drug Manufacturing License (Class C), Expanding CDMO Services to Commercialization
Porton Advanced’s UC-MSCs Cell Bank for Exosome Manufacturing Receives U.S. FDA Drug Master File (DMF) Acceptance
Porton Advanced Powers Qihan Biotech’s Second FDA IND Approval for Allogeneic Dual-Targeting CAR-T Product
China-US Dual Filing Success:Porton Advanced’s End-to-End Bacterial Vector CDMO Solution Accelerates NMPA Approval of Salvectors’ Innovative Oncolytic Bacteria Therapy
Porton Advanced Stem Cell Exosomes Granted INCI Status, Advancing into Global Cosmetic Ingredient Market
Porton Advanced and Dark Horse Consulting Group Announce Memorandum of Understanding Providing A Streamlined Path to Conducting IITs in China